DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of ...
PrimeC has been given an ‘Orphan Drug’ status by the FDA (Food and Drug Administration) and EMA (European Medicines Agency).
| Avoid common pitfalls in EU orphan drug market access—learn how local expertise can help navigate pricing, reimbursement, ...
NICE publishes final draft guidance recommending efanesoctocog alfa as an option for treating and preventing bleeding in ...
Porosome Therapeutics, Inc. (Porosome Therapeutics) today announced the Orphan Drug Designation of its cystic fibrosis therapy by the Food and Drug Administration (FDA). On February 10 ...
Faron Pharmaceuticals Ltd | Company announcement | March 03, 2025 at 14:00:00 EET Inside Information: FDA Grants Orphan Drug Designation for Bexmarilimab in MDS Key highlightsOrphan Drug Designation f ...
As we observe Rare Disease Day today, let us take a look at seven drugs poised to be approved to address rare diseases in ...
February 28, 2025 (Investorideas.com Newswire) Investorideas.com, a global news source and expert investing resource, ...
Hosted on MSN3d
Neurotech receives positive opinion for orphan status in Rett Syndrome from European drug regulatorNeurotech has received positive feedback from the European Medicines Agency (EMA) on its orphan drug application for NTI164 ...
The Food and Drug Administration (FDA) has granted Orphan Drug designation to EXG-34217 for the treatment of telomere biology disorders.
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading provider of cutting-edge technology solutions ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback